GW873140

DRUG7 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare, GlaxoSmithKline

Conditions

HIV InfectionHIV InfectionsInfection, Human Immunodeficiency Virus I

Phase 2

GW873140 to Treat HIV-1 Infected Adults

CompletedNCT00076284

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2004-01-31End: 2005-03-31Target: 20Updated: 2008-03-04

GW873140 In Combination With Kaletra In HIV Infected Subjects

TerminatedNCT00102778

ViiV HealthcareHIV Infection, Infection, Human Immunodeficiency Virus I

Start: 2004-12-31End: 2007-09-30Target: 175Updated: 2017-05-30

GW873140 In Combination With Combivir In HIV Infected Subjects

TerminatedNCT00104429

ViiV HealthcareHIV Infection, Infection, Human Immunodeficiency Virus I

Start: 2005-01-31End: 2006-01-31Target: 125Updated: 2017-05-30

Phase 3

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

TerminatedNCT00123890

GlaxoSmithKlineHIV Infection

Start: 2005-06-30End: 2005-10-31Updated: 2011-03-29

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

TerminatedNCT00197145

ViiV HealthcareInfection, Human Immunodeficiency Virus I

Start: 2005-07-21End: 2007-09-11Updated: 2018-11-02

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects

TerminatedNCT00197197

GlaxoSmithKlineHIV Infection

Start: 2005-07-31End: 2005-10-31Updated: 2011-03-29

Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

TerminatedNCT00297076

GlaxoSmithKlineHIV Infection

Start: 2005-07-31End: 2007-10-31Target: 406Updated: 2009-05-18